Popular on TelAve
- ScaleFibre Launches SmartRIBBON™ High-Density Optical Fibre Cables - 604
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle' - 440
- Phinge To Offer All Third Party Platforms On Netverse The Ability To Run Instant Deals Automatically To Increase Sales During Slow Parts Of The Day - 337
- Starlink Local Installers offers national Starlink installations! - 329
- Phinge Asked Google AI, How Could Netverse Disrupt Crypto Like Bitcoin? Its Answer Might Shock You - 301
- Copper Mountain Technologies Introduces Affordable New VTR0102 and VTR0302 VNAs - 300
- "Has Google AI Surpassed the Collective Intelligence of the World?" Asks Phinge - 259
- Netverse Could Diminish the Reliance on Cyber Security Software & Companies Through its AI, Patented App-less Technologies & Phinge Mobile Hardware - 255
- Phinge Mobile Pop-Up Stores Coming To Cities To Preview Its Upcoming Patented Modular Earbuds & Magnetically Connectable Phones, Tablets Gaming & More - 249
- SecureMaine 2025 is this October 8th in Portland, Maine - 241
Similar on TelAve
- DGiTK – Digital Technologies, LLC Announces Groundbreaking Partnership with Hyperscale Compute Partner to Revolutionize Data Sovereignty in the U.S
- SPOZZ, the Community-Owned Direct-to-Fan Music Ecosystem, adds "BEATS" — a Creator-to-Creator Marketplace
- Unprescribed™ Introduces the Focus, Mood & Mind System™
- $20 Target in Noble Capital Markets Report Supported by Live Stream of 1ST Global Super League Kerala Event from AI Powered Sports Leader: $SEGG
- Newest Mako Smartrobotics™ System Used for First Time in the State Of Illinois for Total Joint Replacement Surgery
- $20 Million Annualized Revenue Projected from 20+ Acquisitions and Scaling of Top Quality Dental Labs Across Florida: Standard Dental Labs $TUTH
- Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular
- David White DDS Advances Implant Dentistry with New Technology Acquisition
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
Vesica Health Granted PLA Billing Code for AssureMDx
TelAve News/10877245
Enabling reimbursement and expanded patient access—Effective January 2026
IRVINE, Calif. - TelAve -- VESICA HEALTH®, INC., a precision diagnostics company improving the early detection and management of bladder cancer, today announced that the American Medical Association (AMA) has granted a Proprietary Laboratory Analysis (PLA) billing code for its AssureMDx™ test. The new code, effective January 2026, represents a critical de-risking milestone in Vesica Health's path to commercialization, establishing a recognized billing pathway that will enable reimbursement and support adoption of AssureMDx across the U.S. healthcare system. This achievement positions Vesica Health to accelerate revenue generation and deliver meaningful near-term value creation for our shareholders, while at the same time expanding access for patients.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on TelAve News
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on TelAve News
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on TelAve News
- DAECO Painting Sets the Gold Standard for High-End Interior Painting Services in Denver, CO
- Boston Industrial Solutions Expands Availability of Industry-Leading Primers to Mexico
- Unprescribed™ Introduces the Focus, Mood & Mind System™
- Texas Mechanic Unveils "Mighty Mule" Experimental Pontiac Engine—Delivering Over Triple the Factory Horsepower
- $20 Target in Noble Capital Markets Report Supported by Live Stream of 1ST Global Super League Kerala Event from AI Powered Sports Leader: $SEGG
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on TelAve News
- AssetHUB and CWP Announce Strategic Partnership to Accelerate Connectivity and Infrastructure
- Newest Mako Smartrobotics™ System Used for First Time in the State Of Illinois for Total Joint Replacement Surgery
- $20 Million Annualized Revenue Projected from 20+ Acquisitions and Scaling of Top Quality Dental Labs Across Florida: Standard Dental Labs $TUTH
- Grok Wrote a Direct Message to Elon Musk Discussing Netverse & Phinge CEOs Challenge to Live Debate & Added "it'd be epic to see you two hash it out"
- Assent Recognized as a Leader in First-Ever Product Compliance Green Quadrant
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Vesica Health, Inc.
0 Comments
Latest on TelAve News
- Cryptocurrency Trading: AHRFD Enters German Market with Institutional-Grade Infrastructure
- TSWHZC Launches Automated Copy Trading Platform for Brazil's 28 Million Crypto Users
- Keyanb Crypto Exchange Unveils Comprehensive Platform Architecture for Chilean Traders Seeking Lower Fees and Enhanced Security
- Phoenix Advocacy Network Launches to Amplify Survivor Voices and Advance Disability Rights
- Matecrypt Platform Delivers Comprehensive Solution for Argentine Traders with 200+ Cryptocurrencies and 2 Million Orders Per Second Processing
- Wzzph Exchange Expands Brazilian Market Access with Comprehensive Trading Platform
- CCHR: Prescription Psychotropics Fuel America's Addiction and Overdose Crisis
- The Truth Behind Egypt's Stolen Legacy: Livestream
- Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
- 'ChilCorp – Water' Builds Momentum After Being Named as a Qualified Team in $119M XPRIZE Water Scarcity Global Competition
- Cryptocurrency Exchange AZETHIO Targets US Market Security Concerns with MPC Technology and 15-Minute KYC Verification
- Gospel Sensation "Bible, Faith, Rembrandt aka BFR, They're Taking the World by Storm
- Durex Products Screen Media Suitable for U.S. FAST 41 Critical Minerals Mining Projects
- SQHWYD Launches Cognitive Finance Platform with Intelligent Trading Technology and Unified DeFi Access for Brazilian Market
- Southland Symphony Orchestra Season Opener – A Musical Mosaic
- Iguabit Unveils Comprehensive Platform Strategy for Brazilian Crypto Traders Seeking Regulated Solutions
- MoArk Dental & Implants Introduces Yomi Robotic Technology for Implant Surgery
- K-Drama Tours Expands Into K-Pop Experiences with New "K-Pop Demon Hunters" Tour in Seoul
- The World's No.1 Superstar™ Unveils Fall Lineup With the Re-Release of Holiday Classics
- Building A Business Website That Works In 2025